P
DEAD

Serial Number

78178624

Owner

Proteom Limited

Attorney

PAMELA S. RATLIFF

Filing Date

Oct 25, 2002

Add to watchlist:

No watchlists yet
View on USPTO

P Trademark

Serial Number: 78178624 • Registration: 3212165

P is a trademark filed by Proteom Limited on October 25, 2002. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Proteom Limited (2 trademarks)

Babraham Hall
Babraham CB2 4AT , GB

Entity Type: 03

Trademark Details

Filing Date

October 25, 2002

Registration Date

February 27, 2007

Published for Opposition

September 27, 2005

Cancellation Date

October 4, 2013

Goods & Services

Computer hardware; data processors; computer software for use in the design or identification and characterization of genes and proteins through bioinformatics and related techniques; computer software for the design and identification of chemical entities for drug discovery research; computer software for use in gene therapy and disease diagnosis; computer software comprised of algorithms for use in analysis and data-mining of sequence chemical databases

Pharmaceutical preparations for therapeutic, prophylactic and or pharmacological purposes, namely, for use in relation to abdominal disease, abnormal substrate concentration, asthenia, atrophy, breast disease, cardiovascular disease, degeneration, dermatological disease, dystrophy, ear, nose, throat disease, endocrine disease, fatigue, gastro-intestinal disorder, genetic disorder, genitourinary disease, growth disorder, hematological disease, immune disorder, immunomodulation, infection, inflammation, injury, metabolic disorder, mouth disease, movement disorder, musculoskeletal disease, neoplasm, neurological, mental and cognitive disorder, nutritional disorder, ocular disease, pain, pregnancy disorder, prophylaxis, renal disease, respiratory disease, sleep disorder, somatosensory disorder, temperature disorder, toxicity and intoxication, ulcer,uterine motility; pharmaceutical preparations comprised of peptides and polypeptides for use in relation to abdominal disease, abnormal substrate concentration, asthenia, atrophy, breast disease, cardiovascular disease, degeneration, dermatological disease, dystrophy,ear, nose, throat disease, endocrine disease, fatigue, gastro-intestinal disorder, genetic disorder, genitourinary disease, growth disorder, hematological disease, immune disorder, immunomodulation, infection, inflammation, injury, metabolic disorder, mouth disease, movement disorder, musculoskeletal disease, neoplasm, neurological, mental and cognitive disorder, nutritional disorder, ocular disease, pain, pregnancy disorder, prophylaxis, renal disease, respiratory disease, sleep disorder, somatosensory disorder, temperature disorder, toxicity and intoxication, ulcer, uterine motility; chemicals for use in biotechnology and chemicals produced through biotechnological processes, namely, vaccines

Chemicals for use in the manufacture of pharmaceuticals, cosmetics, and healthcare products; chemicals for use in science, namely, reagents for scientific research; chemicals for use in biotechnology and chemicals produced through biotechnological processes, namely, therapeutic proteins and biologics for scientific use in drug discovery; peptide sand polypeptide and small molecules for use in scientific research; all of the aforesaid for use in assays, screens and diagnosis

Providing temporary use of online non-downloadable computer software for use in the design or identification and characterization of genes and proteins through bioinformatics related techniques; providing temporary use of online non-downloadable software for the design or identification of chemical entities for drug discovery research; providing temporary use of online non-downloadable computer software for use in gene therapy and disease diagnosis; providing temporary use of online non-downloadable computer software comprised of algorithms for use in analysis and data-mining of sequence and chemical databases; providing databases and online databases featuring complementary peptide sequences to all known genes in the human, bacterial, viral, animal and plant genomes; proteomic, genomic, bioinformatics, chemical and scientific consultation services, namely, providing advice and consultation in the fields of genomics, informatics, study of protein properties molecular design; medical, scientific and biotechnological research, namely, identification and characterization of genes and proteins and the design or identification of chemical entities through bioinformatics and related techniques, and providing consultancy and advisory services relating thereto; consultancy, advice and provision of information relating to drug discovery research, disease diagnosis; design, creation and provision of databases, namely, databases for the identification and characterization of genes, proteins and small molecules; design and creation of computer software for data-mining; design, creation and development of proprietary informatics technology, namely for the location and definition of peptide and small molecule ligands; use of bioinformatics and related techniques to design the core regions of molecular functionality and to enable the generation, design, development and validation of peptide and small molecule ligands for existing and novel targets; prediction and design of peptides from DNA sequence data; data-mining operations; scientific research, namely, identification of targets for therapeutic applications and design of chemical inhibitors, agonists and antagonists; design, optimization and development of chemical inhibitors, agonists and antagonists for specific targets for therapeutic applications; design, creation and provision of informatics based programs designed to monitor and research scientific databases and identify potential leads matched to accompany discovery portfolio; genetic research services, namely, obtaining and analyzing genetic or chemical information; gene sequencing; laboratory research and collaboration with academic research groups in the field of drug discovery and healthcare research; pharmaceutical and bio technical research, namely, collaboration with pharmaceutical and biotechnology companies; drug discovery and development programs; synthesis of peptides and small molecules

Filing History

CANCELLED SEC. 8 (6-YR)
Oct 4, 2013 C8..
CORRECTION UNDER SECTION 7 - PROCESSED
Jan 29, 2009 COC.
ASSIGNED TO PARALEGAL
Jan 6, 2009 PLGL
TEAS SECTION 7 REQUEST RECEIVED
Nov 20, 2008 ES7R
REGISTERED-PRINCIPAL REGISTER
Feb 27, 2007 R.PR
1(B) BASIS DELETED; PROCEED TO REGISTRATION
Jan 11, 2007 DP1B
NOTICE OF ALLOWANCE CANCELLED
Dec 18, 2006 IUCN
TEAS DELETE 1(B) BASIS RECEIVED
Dec 18, 2006 D1BR
POST PUBLICATION AMENDMENT - ENTERED
Jun 21, 2006 CHPB
SOU EXTENSION 1 GRANTED
Jun 20, 2006 EX1G
SOU EXTENSION 1 FILED
Jun 20, 2006 EXT1
SOU TEAS EXTENSION RECEIVED
Jun 20, 2006 EEXT
FAX RECEIVED
Jun 20, 2006 FAXX
NOA MAILED - SOU REQUIRED FROM APPLICANT
Dec 20, 2005 NOAM
POST PUBLICATION AMENDMENT - ENTERED
Oct 27, 2005 CHPB
PUBLISHED FOR OPPOSITION
Sep 27, 2005 PUBO
NOTICE OF PUBLICATION
Sep 7, 2005 NPUB
LAW OFFICE PUBLICATION REVIEW COMPLETED
Jun 30, 2005 PREV
ASSIGNED TO LIE
Jun 20, 2005 ALIE
APPROVED FOR PUB - PRINCIPAL REGISTER
Jun 15, 2005 CNSA
AMENDMENT FROM APPLICANT ENTERED
Jun 14, 2005 ACEC
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 26, 2005 CRFA
PAPER RECEIVED
May 26, 2005 MAIL
NON-FINAL ACTION E-MAILED
Nov 22, 2004 GNRT
NON-FINAL ACTION WRITTEN
Nov 22, 2004 CNRT
FAX RECEIVED
May 28, 2004 FAXX
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 28, 2004 CRFA
NOTICE OF UNRESPONSIVE AMENDMENT - E-MAILED
May 1, 2004 GAUD
CASE FILE IN TICRS
Oct 30, 2003 CFIT
CORRESPONDENCE RECEIVED IN LAW OFFICE
Sep 29, 2003 CRFA
PAPER RECEIVED
Sep 29, 2003 MAIL
NON-FINAL ACTION E-MAILED
Mar 25, 2003 GNRT
ASSIGNED TO EXAMINER
Mar 24, 2003 DOCK
PAPER RECEIVED
Oct 31, 2002 MAIL